Acute-On-Chronic Liver Failure Clinical Trial
Official title:
Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure- A Cross-Sectional Study
Verified date | April 2023 |
Source | Institute of Liver and Biliary Sciences, India |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Monitoring and Assessment: Transient Elastography will be performed in morning hours using the FibroScan apparatus (Echosens), which consists of a 5-MHz ultrasound transducer probe mounted on the axis of a vibrator. The tip of the transducer (M-or XL probe) will be covered with a drop of gel and placed perpendicularly in the intercostal space, with the patient lying in dorsal decubitus position with the right arm in the maximal abduction. Under control, in time motion and in A-mode, the operator will choose a liver portion within the right liver lobe, at least 6-cm thick and free of large vascular structures, and the gallbladder. Liver stiffness (LS) will be measured on a cylinder of hepatic tissue of 1 cm of diameter and 4 cm of length. For assessing the splenic stiffness (SS), the patient will be in supine position with left arm in maximum abduction. Ultrasonography will be used to identify and locate the spleen parenchyma, to choose the right place for SS measurement, and to measure the spleen diameter (long axis). Transducer will be placed in the left intercostal spaces, with location indicated by the ultrasound. A median value of 10 successful acquisitions, expressed in kPa, will be kept as a representative of the LS and SS measurements. The LS and SS measurement failure will be recorded when no value will be obtained after at least 10 shots. The results will be considered unreliable in the following circumstances: valid shots fewer than 10, success rate < 60%, or interquartile range / LS >30 %. Liver and splenic stiffness, LSPS score (LS measurement × spleen diameter / platelet count), Platelet count to spleen diameter ratio (PSR) will be calculated. Patient will also undergo upper g.i. endoscopy on same day. HVPG and TJLB will be done if indicated. The study will assess whether the stiffness scores correlate with presence of esophageal varices. Optimum cutoffs will be calculated for predicting the presence of esophageal varices. - Study design: A Cross-Sectional Study - Study period: 12 months - Sample size with justification: Consecutive Patients of ACLF from approval of study to 12 months. ACLF patients will be screened and eligible patients will be taken in to the study. - Intervention: Patients of ACLF will undergo upper g.i. endoscopy, liver and splenic stiffness measurement. HVPG and TJLB will be done in the patients only if clinically indicated.
Status | Completed |
Enrollment | 216 |
Est. completion date | September 30, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Patients of ACLF (APASL criteria). Exclusion Criteria: 1. Age < 18 and > 70 years 2. moderate to severe ascites 3. Portal Vein Thrombosis 4. Hepatocellular carcinoma 5. space occupying lesion liver 6. heart failure 7. biliary obstruction 8. prior variceal endotherapy or ongoing beta blocker treatment for varices 9. pregnancy 10. ICD / pacemaker 11. ongoing treatment for HBV 12. HCV or ended within 3 months 13. No consent. |
Country | Name | City | State |
---|---|---|---|
India | Institute of Liver & Biliary Sciences | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
Institute of Liver and Biliary Sciences, India |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the utility of liver and splenic stiffness and develop a model to predict presence of esophageal varices needing treatment in patients of ACLF. | Utility will be find out from the cut off values of ROC with maximum sensitivity. | Day 1 | |
Secondary | To study the correlation of liver and splenic stiffness with grade of esophageal varices. | Day 1 | ||
Secondary | To study utility of liver and splenic stiffness in evaluating esophageal varices in comparison with other non-invasive tests. | Day 1 | ||
Secondary | To study correlation of liver and splenic stiffness with HVPG in patients of ACLF. | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05985863 -
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04822922 -
Safety of UC-MSC Transfusion for ACLF Patients
|
Phase 2 | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Withdrawn |
NCT05940610 -
The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05036031 -
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
|
||
Recruiting |
NCT05019352 -
Cytokine Adsorption in Acute-on-chronic Liver Failure
|
N/A | |
Recruiting |
NCT05421351 -
Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
|
||
Completed |
NCT02321371 -
Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.
|
N/A | |
Not yet recruiting |
NCT06069037 -
SALT for Treatment of Patients With Early ACLF
|
N/A | |
Completed |
NCT02965560 -
Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
|
||
Recruiting |
NCT03713489 -
Platelet Transfusion in HBV-related acute-on Chronic Liver Failure
|
N/A | |
Withdrawn |
NCT03629015 -
Safety Study of Stemchymal® in Acute Liver Failure
|
Phase 1 | |
Recruiting |
NCT04621812 -
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
|
||
Recruiting |
NCT04157465 -
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
|
N/A | |
Suspended |
NCT03737448 -
TRimetazidine for acUte on Chronic Liver Failure STudy
|
Phase 1 | |
Recruiting |
NCT06128421 -
Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk
|
N/A | |
Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
Completed |
NCT04238416 -
Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF
|
Phase 1 | |
Completed |
NCT03456518 -
Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease
|
||
Recruiting |
NCT03987893 -
PEG3350 in ACLF With Hepatic Encephalopathy
|
Phase 4 |